Australia - angielski - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - carvedilol, quantity: 12.5 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; magnesium stearate; colloidal anhydrous silica; povidone; crospovidone; iron oxide yellow; iron oxide red - dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to moderate (nyha class ii & iii) congestive heart failure, as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators). indications as at 24 january 2002: dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators). indications as at 3 march 2003: dilatrend is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Australia - angielski - Department of Health (Therapeutic Goods Administration)

pharmaco australia ltd - carvedilol, quantity: 6.25 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; sucrose; magnesium stearate; colloidal anhydrous silica; povidone; crospovidone; iron oxide yellow - dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to moderate (nyha class ii & iii) congestive heart failure, as an adjunct to conventional treatments (e.g diuretics, digoxin, ace inhibitors and vasodilators). indications as at 24 january 2002: dilatrend is indicated for the treatment of mild to moderate hypertension. data have not been provided to support the use of this drug in severe hypertension or renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators). indications as at 3 march 2003: dilatrend is indicated for the treatment of hypertension. data have not been provided to support the use of this drug in renovascular disease. dilatrend is indicated for the treatment of patients with symptomatic mild to severe (nyha class ii - iv) congestive heart failure (chf) as an adjunct to conventional treatments (e.g. diuretics, digoxin, ace inhibitors and vasodilators).

Szwajcaria - francuski - Swissmedic (Swiss Agency for Therapeutic Products)

cps cito pharma services gmbh - carvedilolum - comprimés - carvedilolum 12.5 mg, saccharum 12.5 mg, lactosum monohydricum 59.1 mg, povidonum k 25, silica colloidalis anhydrica, crospovidonum, magnesii stearas, e 172 (flavum), e 172 (rubrum), pro compresso. - l'alpha et le bêta-bloquants - synthetika

Szwajcaria - francuski - Swissmedic (Swiss Agency for Therapeutic Products)

cps cito pharma services gmbh - carvedilolum - comprimés - carvedilolum 25 mg, saccharum 25 mg, lactosum monohydricum 10 mg, povidonum k 25, silica colloidalis anhydrica, crospovidonum, magnesii stearas, pro compresso. - l'alpha et le bêta-bloquants - synthetika

Szwajcaria - francuski - Swissmedic (Swiss Agency for Therapeutic Products)

cps cito pharma services gmbh - carvedilolum - comprimés - carvedilolum 6.25 mg, saccharum 21.25 mg, lactosum monohydricum 51.8 mg, povidonum k 25, silica colloidalis anhydrica, crospovidonum, magnesii stearas, e 172 (flavum), pro compresso. - l'alpha et le bêta-bloquants - synthetika

Australia - angielski - Department of Health (Therapeutic Goods Administration)

roche products pty ltd - carvedilol -

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - carvedilol 12.5mg - tablet - 12.5 mg - active: carvedilol 12.5mg excipient: colloidal silicon dioxide crospovidone iron oxide red iron oxide yellow lactose monohydrate magnesium stearate povidone sucrose - indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - carvedilol 25mg - tablet - 25 mg - active: carvedilol 25mg excipient: colloidal silicon dioxide crospovidone lactose monohydrate magnesium stearate povidone sucrose - indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

Nowa Zelandia - angielski - Medsafe (Medicines Safety Authority)

pharmaco (nz) ltd - carvedilol 6.25mg - tablet - 6.25 mg - active: carvedilol 6.25mg excipient: colloidal silicon dioxide crospovidone iron oxide yellow lactose monohydrate magnesium stearate povidone sucrose - indicated for the management of essential hypertension. it can be used alone or in combination with other antihypertensive agents (e.g. calcium channel blockers, diuretics).

Turcja - turecki - TİTCK (Türkİye İlaç Ve Tibbİ Cİhaz Kurumu)

deva - karvedilol - allegra